Randomized controlled trial of twice-daily versus alternate-day oral iron therapy in the treatment of iron-deficiency anemia
Rahul Kaundal(Post Graduate Institute of Medical Education and Research), Deepesh Lad(Post Graduate Institute of Medical Education and Research), Alka Khadwal(Post Graduate Institute of Medical Education and Research), Nishant Jindal(Post Graduate Institute of Medical Education and Research), Rajeev Sandal(Post Graduate Institute of Medical Education and Research), Ankur Jain(Post Graduate Institute of Medical Education and Research), Aditya Jandial(Post Graduate Institute of Medical Education and Research), Ram Vasudevan Nampoothiri(Post Graduate Institute of Medical Education and Research), Reena Das(Post Graduate Institute of Medical Education and Research), Kundan Mishra(Post Graduate Institute of Medical Education and Research), Ashok Meshram(Post Graduate Institute of Medical Education and Research), Prateek Bhatia(Post Graduate Institute of Medical Education and Research), Charanpreet Singh(Post Graduate Institute of Medical Education and Research), Rintu Sharma(Post Graduate Institute of Medical Education and Research), Arihant Jain(California University of Pennsylvania), Subhash Varma(Post Graduate Institute of Medical Education and Research), Pankaj Malhotra(Post Graduate Institute of Medical Education and Research), Deepak Goni(Post Graduate Institute of Medical Education and Research), Neelam Varma(Nagpur Institute of Technology), Niranjan Khaire(Post Graduate Institute of Medical Education and Research), Gaurav Prakash(Post Graduate Institute of Medical Education and Research)
Cited by 65
Related Papers
Global Burden of Multiple Myeloma
|JAMA Oncology|2018|631
X-Linked Dyskeratosis Congenita Is Predominantly Caused by Missense Mutations in the DKC1 Gene
|The American Journal of Human Genetics|1999|264
Visceral leishmaniasis associated hemophagocytic lymphohistiocytosis – Case report and systematic review
|Journal of Infection|2008|114
Imatinib has adverse effect on growth in children with chronic myeloid leukemia
|Pediatric Blood & Cancer|2011|95
Growth failure in children with chronic myeloid leukemia receiving imatinib is due to disruption of GH/IGF‐1 axis
|Pediatric Blood & Cancer|2013|85